Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca
Scientific Title
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition